News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ear Disease Biotech Otonomy, Inc. Files For An $86 Million IPO



7/14/2014 6:47:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Otonomy, a late-stage biotech developing sustained-exposure treatments for ear diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering. Otonomy plans to submit an NDA in the 1H15 for its lead candidate, AuriPro, which recently completed Phase 3 trials for middle ear effusion during TTP surgery.

Otonomy's second candidate is in Phase 2b trials for Ménière's disease, and it has a preclinical treatment for tinnitus. Another ear disease biotech, Switzerland-based Auris Medical ( EARS ), filed to raise the same amount just two weeks ago. Auris is in Phase 3 development for acute inner ear tinnitus.

Help employers find you! Check out all the jobs and post your resume.

Read at Nasdaq
Read at News Release
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES